# Simulations Plus, Inc. stock analysis

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans

## Market evidence and data freshness

The public preview recorded Simulations Plus, Inc. at 18.48 USD on 2026-09-28T20:00:00.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-09-30 through 2026-09-15 across 1244 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying Simulations Plus, Inc. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/slp)